Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

Triple-negative breast cancer is a heterogeneous disease and specific therapies have not
been available for a long time. Therefore, conventional chemotherapy is still considered the …

Copper serves as a co-factor for a host of metalloenzymes that contribute to malignant
progression. The orally bioavailable copper chelating agent tetrathiomolybdate (TM) has …

Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-
mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) …

Importance The value of platinum-based adjuvant chemotherapy in patients with triple-
negative breast cancer (TNBC) remains controversial, as does whetherBRCA1andBRCA2 …

Triple-negative breast cancer (TNBC) is an aggressive breast type of cancer with no
expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal …

Commensal bacteria and other microorganisms that reside in the human body are closely
associated with the development and treatment of cancers. Recently, tumor microbiome …

Background Triple negative breast cancer (TNBC) represents 15–20% of breast cancers.
Due to its heterogeneity and high rates of relapse, there is a need to optimize treatment …

While tremendous improvement has been made for the treatment of breast cancers, the
treatment of triple negative breast cancer (TNBC) still remains a challenge due to its …

Tumor associated fibroblasts (TAFs) are key stromal cells mediating the desmoplastic
reaction and being partially responsible for the drug-resistance and immunosuppressive …